Foconsci Chemical Industry, Department of Biotechnology, China
Research Article
Placebo-Controlled Study of AminoTriComplex in Metastatic Prostate Cancer: Regulation of Key Biomarkers, Sharp Decrease in PSA and Proinflammatory Cytokines, and Clinical Improvement in 95% of Patients
Author(s): Alexandre Tavartkiladze*, Gaiane Simonia, Russel J Reiter, Ruite Lou, Nana Okrostsvaridze, Pati Revazishvili, Irine Andronikashvili, Givi Tavartkiladze, Pirdara Nozadze, Tamar Japaridze, Tatia Potskhoraia and Malvina Javakhadze
Background: Metastatic prostate cancer remains one of the leading causes of cancer-related morbidity and mortality
in men worldwide. Despite advances in Androgen Deprivation Therapies (ADT), chemotherapy, targeted agents, and
immunotherapies, many patients develop therapeutic resistance and experience significant toxicities. Dysregulated
metabolic and inflammatory pathways, such as heightened glycolysis, increased proinflammatory cytokines, elevated
Matrix Metalloproteinases (particularly MMP-9), and Androgen Receptor splice variants (e.g., AR-V7), can further
drive disease progression. Emerging evidence suggests that optimizing host biology through circadian rhythm support,
antioxidant defense, and modulation of immune function may confer therapeutic benefits.
We conducted a double-blind, placebo-controlled study in 52 men to evaluate the effects.. View More»
DOI:
10.35248/IGOA.25.10.248